Timothy M. Cox, Ph.D.
Affiliations: | Medicine | University of Cambridge, Cambridge, England, United Kingdom |
Area:
lysosomal storage disordersWebsite:
http://www.sid.cam.ac.uk/aboutus/people/person.html?crsid=tmc12Google:
"Timothy Cox"Mean distance: 9.18 | S | N | B | C | P |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Beck M, Cox TM. (2019) Comment: Why are females with Fabry disease affected? Molecular Genetics and Metabolism Reports. 21: 100529 |
| Pavlova EV, Shatunov A, Wartosch L, et al. (2019) The lysosomal disease caused by mutant VPS33A. Human Molecular Genetics |
| Serratrice C, Cox TM, Leguy-Seguin V, et al. (2019) Splenic Artery Aneurysms, A Rare Complication of Type 1 Gaucher Disease: Report of Five Cases. Journal of Clinical Medicine. 8 |
| Weinreb NJ, Cox TM, Mistry PK, et al. (2019) Biomarker Response to Oral Eliglustat in Adults with Gaucher Disease Type 1: Results from 4 Completed Clinical Trials Blood. 134: 4859-4859 |
| Donald A, Jones SA, Vellodi A, et al. (2019) From birth to the sixth decade - A natural history study of 42 patients with neuronopathic Gaucher disease Molecular Genetics and Metabolism. 126 |
| Cox TM, Charrow J, Lukina E, et al. (2019) Effects of oral eliglustat on skeletal manifestations in patients with type 1 Gaucher disease: Results from four completed clinical trials after long-term treatment Molecular Genetics and Metabolism. 126 |
| Pohl S, Angermann A, Jeschke A, et al. (2018) The lysosomal protein arylsulfatase B is a key enzyme involved in skeletal turnover. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research |
| Cachon-Gonzalez MB, Zaccariotto E, Cox TM. (2018) Genetics and Therapies for GM2 Gangliosidosis. Current Gene Therapy |
| Mistry PK, Charrow J, Cox T, et al. (2018) Long-Term Effects of Oral Eliglustat on Skeletal Manifestations of Gaucher Disease Type 1: Results from Four Completed Clinical Trials Blood. 132: 2396-2396 |
| Smith NJC, Fuller M, Saville JT, et al. (2017) Reduced cerebral vascularisation in experimental neuronopathic Gaucher disease. The Journal of Pathology |